Home
/
Anixa Biosciences Inc
/
Financials
/
Quarterly
Anixa Biosciences Inc — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Anixa Biosciences Inc filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2024
Apr 30, 2024
$210.0K
Jun 4, 2024
Q3
2023
Jul 31, 2023
$210.0K
Sep 6, 2023
Q2
2023
Apr 30, 2023
$210.0K
Jun 14, 2023
Q2
2022
Apr 30, 2022
$513.0K
Jun 10, 2022
Q1
2022
Jan 31, 2022
$513.0K
Mar 11, 2022
Q3
2022
Jul 31, 2021
$513.0K
Sep 9, 2022
Q1
2021
Jan 31, 2021
$512.5K
Mar 11, 2021
Q3
2019
Jul 31, 2019
$250.0K
Sep 6, 2019
Q2
2020
Apr 30, 2019
$250.0K
Jun 9, 2020
Q3
2019
Jul 31, 2018
$362.5K
Sep 6, 2019
Q2
2019
Apr 30, 2018
$750.0K
Jun 12, 2019
Q3
2018
Jul 31, 2017
$362.5K
Sep 7, 2018
Q3
2017
Jul 31, 2016
$100.0K
Sep 8, 2017
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2024
Jul 31, 2023
$210.0K
Sep 6, 2024
Q2
2024
Apr 30, 2023
$210.0K
Jun 4, 2024
Q3
2022
Jul 31, 2021
$513.0K
Sep 9, 2022
Q2
2022
Apr 30, 2021
$513.0K
Jun 10, 2022
Q1
2022
Jan 31, 2021
$513.0K
Mar 11, 2022
Q3
2020
Jul 31, 2019
$250.0K
Sep 8, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2016
Jul 31, 2016
$100.0K
Aug 19, 2016
Q3
2016
Jul 31, 2015
$95.0K
Aug 19, 2016
Q2
2016
Apr 30, 2015
$25.0K
May 20, 2016
Q1
2016
Jan 31, 2015
$9.14M
Feb 19, 2016
Q3
2015
Jul 31, 2014
$1.19M
Aug 18, 2015
Q2
2015
Apr 30, 2014
$1.11M
May 22, 2015
Q3
2013
Jul 31, 2013
$2.1K
Sep 20, 2013
Q2
2013
Apr 30, 2013
$2.1K
Jun 19, 2013
Q1
2013
Jan 31, 2013
$2.1K
Mar 25, 2013
Q3
2013
Jul 31, 2012
$249.5K
Sep 20, 2013
Q2
2013
Apr 30, 2012
$248.1K
Jun 19, 2013
Q1
2013
Jan 31, 2012
$449.2K
Mar 25, 2013
Q3
2012
Jul 31, 2011
$450.4K
Sep 14, 2012
Q2
2012
Apr 30, 2011
$86.9K
Jun 14, 2012
Q1
2012
Jan 31, 2011
$17.0K
Mar 16, 2012
Q3
2011
Jul 31, 2010
$58.0K
Oct 14, 2011
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Jan 31, 2026
($2.57M)
Mar 9, 2026
Q3
2025
Jul 31, 2025
($2.26M)
Sep 10, 2025
Q2
2025
Apr 30, 2025
($2.79M)
May 28, 2025
Q1
2026
Jan 31, 2025
($3.18M)
Mar 9, 2026
Q3
2025
Jul 31, 2024
($3.28M)
Sep 10, 2025
Q2
2025
Apr 30, 2024
($3.14M)
May 28, 2025
Q1
2025
Jan 31, 2024
($3.26M)
Mar 11, 2025
Q3
2024
Jul 31, 2023
($2.51M)
Sep 6, 2024
Q2
2024
Apr 30, 2023
($2.29M)
Jun 4, 2024
Q1
2024
Jan 31, 2023
($2.32M)
Mar 12, 2024
Q3
2023
Jul 31, 2022
($2.75M)
Sep 6, 2023
Q2
2023
Apr 30, 2022
($3.54M)
Jun 14, 2023
Q1
2023
Jan 31, 2022
($3.83M)
Mar 17, 2023
Q3
2022
Jul 31, 2021
($4.33M)
Sep 9, 2022
Q2
2022
Apr 30, 2021
($2.40M)
Jun 10, 2022
Q1
2022
Jan 31, 2021
($2.21M)
Mar 11, 2022
Q3
2021
Jul 31, 2020
($2.56M)
Sep 1, 2021
Q2
2021
Apr 30, 2020
($2.64M)
Jun 10, 2021
Q1
2021
Jan 31, 2020
($2.59M)
Mar 11, 2021
Q3
2020
Jul 31, 2019
($2.14M)
Sep 8, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2026
Jan 31, 2026
($2.72M)
Mar 9, 2026
Q3
2025
Jul 31, 2025
($2.44M)
Sep 10, 2025
Q2
2025
Apr 30, 2025
($3.00M)
May 28, 2025
Q1
2026
Jan 31, 2025
($3.39M)
Mar 9, 2026
Q3
2025
Jul 31, 2024
($3.59M)
Sep 10, 2025
Q2
2025
Apr 30, 2024
($3.47M)
May 28, 2025
Q1
2025
Jan 31, 2024
($3.61M)
Mar 11, 2025
Q3
2024
Jul 31, 2023
($2.84M)
Sep 6, 2024
Q2
2024
Apr 30, 2023
($2.56M)
Jun 4, 2024
Q1
2024
Jan 31, 2023
($2.56M)
Mar 12, 2024
Q3
2023
Jul 31, 2022
($2.80M)
Sep 6, 2023
Q2
2023
Apr 30, 2022
($3.59M)
Jun 14, 2023
Q1
2023
Jan 31, 2022
($3.88M)
Mar 17, 2023
Q3
2022
Jul 31, 2021
($4.39M)
Sep 9, 2022
Q2
2022
Apr 30, 2021
($2.44M)
Jun 10, 2022
Q1
2022
Jan 31, 2021
($2.23M)
Mar 11, 2022
Q3
2021
Jul 31, 2020
($2.44M)
Sep 1, 2021
Q2
2021
Apr 30, 2020
($2.67M)
Jun 10, 2021
Q1
2021
Jan 31, 2020
($2.63M)
Mar 11, 2021
Q3
2020
Jul 31, 2019
($2.18M)
Sep 8, 2020